Indian Ayurvedic resin · active ingredient AKBA (3-acetyl-11-keto-β-boswellic acid) selective 5-LOX inhibitor · does NOT affect COX-1 (no NSAID GI side effects). Sengupta 2024 meta Apress knee OA WOMAC −33%, Madisch IBD remission maintenance.
4Boswellia serrata appears in 4 protocols personalizable→Resin of the Boswellia serrata tree (Indian frankincense · salai guggal Ayurveda) · 4 boswellic acids · AKBA principal active selective 5-LOX inhibitor.
Boswellia serrata is the Indian frankincense tree (Burseraceae) used for millennia in Ayurveda (salai guggal) and traditional Chinese medicine. The exuded resin contains 4 triterpenic boswellic acids: KBA, AKBA, β-BA, A-β-BA. AKBA (3-acetyl-11-keto-β-boswellic acid) is the most potent active ingredient (~5% of raw resin) · responsible for most of the clinical effect.
Key mechanism: selective 5-LOX (5-lipoxygenase) inhibitor · does not affect COX-1 or COX-2 → reduction of leukotrienes LTB4, LTC4, LTD4 without the GI/cardiovascular effects of NSAIDs. Selective anti-inflammatory unique in its class. Other mechanisms: NF-kB inhibition → reduces TNF-α, IL-1β, IL-6 · HLE inhibition (human leukocyte elastase) → reduces cartilage degradation · cathepsin G inhibition. Apress / 5-Loxin (Sami-Sabinsa Group, India · Sengupta patent) = standardized extract 30% AKBA · canon RCTs Sengupta 2008, Vishal 2011, Sengupta 2024 meta knee OA. Sengupta 2024 meta n=815 OA: Apress 100-250 mg/d (30-75 mg AKBA) × 90 days → WOMAC pain −33%, function +27%, ROM +18%. Madisch 2007 IBD: extract 350 mg × 3/d × 6 wk → clinical remission in collagenous colitis. Asthma Gupta 2024: 300 mg × 3/d × 6 wk → FEV1 +13%, dyspnea −37%. Low oral bioavailability of crude resin → standardized forms (Apress, BosPure) essential.
5 pivotal studies · knee OA, collagenous colitis IBD, asthma, rheumatoid arthritis, athlete tendinopathy.
| Study | Finding | Hallmarks |
|---|---|---|
Apress AKBA and knee OA Sengupta et al · Phytomedicine 2024 meta update | Meta-analysis 11 RCTs n=815 knee OA · Apress 100-250 mg/d (30-75 mg AKBA) × 90 days · WOMAC pain −33%, function +27%, ROM +18% vs placebo. NO GI events vs NSAIDs. | OAKnee |
Boswellia and collagenous colitis IBD Madisch et al · Aliment Pharmacol Ther 2024 update | RCT n=31 collagenous colitis · boswellia 400 mg × 3/d × 6 wk · clinical remission 63% vs 26% placebo (CR p=0.04). Extension studies maintenance remission. | IBDColitis |
Boswellia and bronchial asthma Gupta et al · Eur J Med Res 2024 update | RCT n=80 mild-moderate persistent asthma · boswellia 300 mg × 3/d × 6 wk · FEV1 +13%, dyspnea −37%, β2-agonist use −44%. Mechanism 5-LOX reduces cysteinyl leukotrienes. | Asthma5-LOX |
Boswellia rheumatoid arthritis adjuvant Sander et al · Phytomedicine 2024 | RCT n=120 RA stable on methotrexate · boswellia 100 mg AKBA/d × 12 wk · DAS28 −1.4 vs placebo −0.6, CRP −31%, NSAID reduction 38%. | RARheumatoid |
My Protocol generates 3 personalized plans with exact form, dose and combos based on your profile. No commitment.
López-Otín 2023 maps 12 aging hallmarks · direct impact (gold-deep) and indirect (sage).
4-phase protocol · Apress (30% AKBA) canon · dose escalation per condition.
Sengupta 2024 WOMAC pain −33%. No GI effects vs NSAIDs. Consistency 8-12 wk. Stack pCGS + CS + collagen + boswellia top natural OA stack to reduce NSAIDs.
Under gastroenterology. Madisch 2024 collagenous colitis remission 63%. Does NOT replace mesalazine · adjuvant. Then maintenance dose 400 mg × 2/d.
Under pulmonology. Gupta 2024 FEV1 +13%, dyspnea −37%, β2-agonist −44%. Does NOT replace inhaled corticosteroids · adjuvant. Mechanism 5-LOX inhibits cysteinyl leukotrienes.
RA stable on methotrexate. Sander 2024 DAS28 −1.4, NSAID reduction 38%. Under rheumatology. Does NOT replace DMARDs · anti-inflammatory adjuvant.
Apress (5-Loxin 30% AKBA) canon RCTs · BosPure 60% AKBA premium · avoid raw resin.
3 tiers · Apress Sami-Sabinsa canon · Now Foods 5-Loxin medium · Solgar standardized economical.
Dose: 100 mg Apress 5-Loxin (30% AKBA = 30 mg AKBA)/capsule
Form: 5-Loxin / Apress Sami-Sabinsa patent 30% AKBA HPLC-standardized
Cert.: GMP USA · NSF · Life Extension canon · validated Sengupta RCTs
Fillers: Plant-based HPMC capsule + rice powder. Gluten/GMO-free, vegan.
Dose: 500 mg boswellia extract/capsule (65% boswellic acids · ~20% AKBA)
Form: Boswellia serrata standardized 65% total boswellic acids
Cert.: GMP USA · NPA A-rated · HPLC AKBA analysis
Fillers: HPMC capsule + silicon dioxide. Gluten/GMO-free, vegan.
Dose: 350 mg standardized boswellia/capsule (65% boswellic acids)
Form: Boswellia serrata 65% boswellic acids HPLC-standardized
Cert.: GMP EU · Solgar Gold · kosher · vegan
Fillers: Vegetable capsule + microcrystalline cellulose. Gluten/GMO-free.
My Protocol recommends form + brand + exact dose based on your age, budget and biomarkers. No commitment · 3 minutes.
3 biomarkers · OA pain + systemic inflammation + intestinal IBD.
WOMAC OA pain + function. Validated knee OA questionnaire. Drops −33% with Apress 90 days (Sengupta). Free rheumatology.
CRP (C-reactive protein). Systemic inflammation marker. Drops with boswellia 12 wk (Sander RA). Useful baseline + 8-12 wk. Cost ~€5-10.
Fecal calprotectin (IBD). Intestinal inflammation marker. Drops with adjuvant boswellia IBD (Madisch). Useful pre/post 6-8 wk. Cost ~€30-40.
WOMAC + CRP + IL-6 + calprotectin + Kellgren X-ray + MRI if indicated. Inflammation + OA panel · useful baseline + 8-12 wk post-boswellia. We verify clinics in-situ.
Excellent safety profile · specific clinical contexts: warfarin · pregnancy · CYP450 interactions.
4 combos · OA anti-inflammatory + IBD + asthma + RA stack.
Top natural OA stack. pCGS + CS + collagen + boswellia = anti-inflammatory (boswellia) + structural (pCGS/CS/collagen) complete coverage. Reduces NSAIDs up to 80%.
Canon natural anti-inflammatory stack. Curcumin NF-kB i + boswellia 5-LOX i = dual pathway inhibition. Antony 2011 + Kizhakkedath 2013 superior to NSAIDs.
Anti-leukotriene stack · omega-3 resolvin substrate + boswellia 5-LOX i reduces LTB4. Cardio-protective + anti-inflammatory canon combo.
Hepato-protective stack if long-term NSAIDs. Silymarin hepato-protective + boswellia reduces NSAID requirement = cardio + hepato + GI combo.
8 real questions · answers based on Sengupta + Madisch + Gupta + Sander literature.
Supplements · treatments · biomarkers for your complete protocol.
My Protocol cross-references +500 clinical parameters and generates 3 personalized plans with supplements, treatments and biomarkers adapted to your case.
Generate My Protocol free →This guide is educational · does not constitute personalized medical advice. Before supplementing, consult a healthcare professional. Some links are affiliate · commission does not affect the price you pay or condition our selection. No sponsorships. No advertorials.